|
KMID : 1144820220280020067
|
|
대한의생명과학회지
2022 Volume.28 No. 2 p.67 ~ p.82
|
|
|
Comparison of COVID-19 Vaccines Introduced in Korea
|
|
Lee Chang-Gun
Lee Dong-Sup
|
|
|
Abstract
|
|
|
|
The prevalence of SARS-CoV-2 led to inconsistent public health policies that resulted in COVID-19 containment failure. These factors resulted in increased hospitalization and death. To prevent viral spread and achieve herd immunity, the only safe and effective measure is to provide to vaccinates. Ever since the release of the SARS-CoV-2 nucleotide sequence in January of 2020, research centers and pharmaceutical companies from many countries have developed different types of vaccines including mRNA, recombinant protein, and viral vector vaccines. Prior to initiating vaccinations, phase 3 clinical trials are necessary. However, no vaccine has yet to complete a phase 3 clinical trial. Many products obtained "emergency use authorization" from governmental agencies such as WHO, FDA etc. The Korean government authorized the use of five different vaccines. The viral vector vaccine of Oxford/AstraZeneca and the Janssen showed effectiveness of 76% and 66.9%, respectively. The mRNA vaccine of Pfizer-BioNTech and Moderna showed effectiveness of 95% and 94.1%, respectively. The protein recombinant vaccine of Novavax showed an effectiveness of 90.4%. In this review, we compared the characteristics, production platform, synthesis principles, authorization, protective effects, immune responses, clinical trials and adverse effects of five different vaccines currently used in Korea. Through this review, we conceptualize the importance of selecting the optimal vaccine to prevent the COVID-19 pandemic.
|
|
|
KEYWORD
|
|
|
SARS-CoV-2, COVID-19, Clinical trial phases, Oxford/AstraZeneca COVID-19 vaccine, Johnson & Johnson Janssen COVID-19 vaccine, Pfizer-BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine, Novavax COVID-19 vaccine
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|